2-Chloro-2'-deoxyadenosine: Clinical applications in hematology

Blood Reviews

Volumn 10, Issue 3, 1996, Pages 148-166

  Delannoy, A ^a,b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Hospital de Jolimont   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CLADRIBINE; CYTOTOXIC AGENT; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PREDNISONE;

BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; CYTOPENIA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; HAIRY CELL LEUKEMIA; HEADACHE; HEMATOLOGY; HUMAN; INFECTION; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LYMPHOCYTE; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAXIMUM PERMISSIBLE DOSE; MOTOR DYSFUNCTION; NAUSEA; NEUROTOXICITY; PHLEBITIS; PRIORITY JOURNAL; RASH; REVIEW; STEVENS JOHNSON SYNDROME; STRUCTURE ACTIVITY RELATION; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0029804405     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(96)90022-3     Document Type: Article

References (160)

1. Beutler E, Piro L D, Saven A et al. 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymph 1991; 5:1-8.
2. Piro L D, Carrera C J, Beutler E, Carson D A. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72:1069-1073.
3. Piro L D, Carrera C J, Carson D A, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322:1117-1121.
4. Tallman M S, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86:2463-2474.
5. Saven A, Piro L D. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994; 120:784-791.
6. Guchelaar H J, Richel D J, Schaafsma M R. Clinical and texicological aspects of the antineoplastic drug cladribine: a review. Ann Hematol 1994; 69:223-230.
7. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340:952-956.
8. Bryson H M, Sorkin E M. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993; 46:872-894.
9. Poot-Hoeck C, Hiddemann W. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 1995; 6:421-433.
10. Hershfield M S, Mitchell B S. In: Scriver C R, Beaudet A L, Sly W S, Valle D, eds. The metabolic and molecular bases of inherited disease, 7th edn. New York: McGraw-Hill, 1995:1725-1768.
11. Carson D A, Wasson D B, Kaye J et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci 1980; 77:6865-6869.
12. Carson D A, Wasson D B, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62:737-743.
13. Kawasaki H, Carrera C J, Piro L D, Saven A, Kipps T J, Carson D A. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81:597-601.
14. Arnér E S J, Spasokoukotskaja T, Juliusson G, Liliemark J, Eriksson S. Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients. Br J Haematol 1994; 87:715-718.
15. Saven A, Kawasaki H, Carrera C J et al. 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol 1993; 11:671-678.
16. Parker W B, Bapat A R, Shen J X, Townsend A J, Cheng Y C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 1988; 34:485-491.
17. Seto S, Carrera C J, Kubota M, Wasson D B, Carson D A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985; 75:377-383.
18. Carrera C J, Terai C, Lotz M et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. J Clin Invest 1990; 86:1480-1488.
19. Robertson L E, Chubb S, Meyn R E et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-ß-D-arabinosyl-2′-fluoroadenine. Blood 1993; 81:143-150.
20. Albertioni F, Herngren L, Juliusson G, Liliemark J. Protein binding of 2-chloro-2′-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia. Eur J Clin Pharmacol 1994; 46:563-564.
21. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′deoxyadenosine in humans. Cancer Res 1991; 51:5570-5572.
22. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995; 1:385-390.
23. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine (CdA) in cerebrospinal fluid (CSF). Blood 1992; 80 (Suppl 1):471a.
24. Kearns C M, Blakley R L, Santana V M, Crom W R. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res 1994; 54:1235-1239.
25. Kuttesch J F, Nelson J A. Renal handling of 2-deoxyadenosine and adenosine in humans and mice. Cancer Chemother Pharmacol 1982; 8:221-229.23
26. Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10:1514-1518.
27. Saven A, Carrera C J, Carson D A, Beutler E, Piro L D. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymph 1991; Suppl:133-138.
28. Saven A, Cheung W K, Smith I et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol (In press).
29. Albertioni F, Juliusson G, Liliemark J. On the pharmacokinteics of 2-chloro-2′-deoxyadenosine (CdA); metabolism to 2-chloroadenine (Cade) and renal excretion after intravenous and oral administration. Proc Amer Soc Clin Oncol 1994; 13:157a.
30. Spielberger R T, Larson R A, O'Brien S M, Williams S F, Ratain M J. Phase I study of 2-chlorodeoxyadenosine (CdA) by 1 hour bolus infusion in hematologic malignancies. Proc Amer Soc Clin Oncol 1993; 12:1490a.
31. Tan C T C, Guarino L, Tong W P et al. Clinical and pharmacological studies of 2-chlorodeoxyadenosine (2-CdA) in children with advanced hematologic malignancies and solid tumors. Blood 1994; 84 (Suppl): 302a.
32. Weiss G R, Kuhn J G, Rizzo J et al. A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer Chemother Pharmacol 1995; 35:397-402.
33. Tefferi A, Witzig T E, Reid J M, Li C Y, Ames M M. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol 1994; 12:569-574.
34. Santana V M, Mirro J, Harwood F C et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 1991; 9:416-422.
35. Vahdat L, Wong E T, Wile M J, Rosenblum M, Foley K M, Warrell R P. Therapeutic and neutotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 1994; 84:3429-3434.
36. Kobayashi K, Vogelzang N J, O'Brien S M, Schilsky R L, Vokes E E, Ratain M J. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer 1994; 74:168-173.
37. Juliusson G, Lenkei R, Tjønnfjord G, Heldal D, Liliemark J. Low-dose cladribine for symptomatic hairy cell leukaemia. Br J Haematol 1995; 89:637-639.
38. Betticher D C, Fey M F, von Rohr A et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 1994; 5:57-64.
39. Dimopoulos M A, Weber D, Delasalle K B, Keating M, Alexanian R. Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 1995; 6:49-52.
40. O'Brien S, Kurzrock R, Duvic M et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994; 84:733-738.
41. Juliusson G, Heldal D, Hippe E et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13:989-995.
42. Tallman M S, Hakimian D, Variakojis D et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80:2203-2209.
43. Tallman M S, Hakimian D, Zanzig C et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 1995; 13:983-988.
44. Saven A, Lemon R H, Kosty M, Beutler E, Piro L D. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13:570-574.
45. Cheson B D, Vena D A, Foss F M, Sorensen J M. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994; 12:2216-2228.
46. Beutler E, Koziol J A, McMillan R, Sipe J C, Romine J S, Carrera C J. Marrow suppression produced by repeated dose of cladribine. Acta Haematol 1994; 91:10-15.
47. Betticher D C, Fey M F, Rabaglio M et al. Cladribine and severe myelotoxicity. Lancet 1993; 342:1369.
48. Juliusson G, Lenkei R, Tjønnfjord G, Heldal D, Liliemark J. Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocyte-macrophage colony-stimulating factor. Ann Oncol 1995; 6:371-375.
49. O'Brien S, Kantarjian H, Estey E et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994; 330:319-322.
50. von Rohr A, Betticher D, Cerny T, Fey M F, Tobler A. Peripheral blood lymphocyte (PBL) subpopulations in patients treated with 2-chlorodeoxyadenosine (CDA): correlation with infection rate. Blood 1994; 84 (Suppl 1):598a.
51. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994; 83:3672-3681.
52. + lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83:2906-2911.
53. Juliusson G, Johnson SAN, Christiansen I et al. Oral 2-chlorodeoxyadenosine (CDA) as primary treatment for symptomatic chronic lymphocytic leukemia. Blood 1993; 82 (Suppl 1):141a.
54. Delannoy A, Martiat P, Gala J L et al. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995; 9:1130-1135.
55. Sorensen J M, Vena D A, Montello M J, Christian M C, Cheson B D. Treatment of hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine (CdA) under the Group C protocol mechanism. Proc Amer Soc Clin Oncol 1993; 12:302a.
56. Fleishman R A, Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am J Hematol 1995; 48:293.
57. Juliusson G. Immunological and genetic abnormalities in chronic lymphocytic leukaemia. Impact of the purine analogues. Drugs 1994; 47 (Suppl 6):19-29.
58. Zulian G B, Roux E, Tiercy J M et al. Transfusion-associated graft-versus-host disease in a patient treated with Cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis. Br J Haematol 1995; 89:83-89.
59. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11:679-689.
60. Schlaifer D, Brousset P, Delannoy A, Bosly A. Secondary neoplasms emerging among two patients treated with purine analogs. Nouv Rev Fr Hematol 1994; 36:341.
61. Sipe J C, Romine J S, Koziol J A, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344:9-13.
62. Van Den Neste E, Delannoy A, Vandercam B et al. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol (in Press).
63. Saven A, Piro L D. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Leuk Lymph 1993; 11 (Suppl 2):109-114.
64. Piro L D, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymph 1994; 14 (Suppl 1): 121-125.
65. Piro L D, Miller W E, Carrera C J, Carson D A. Beutler E. Hairy cell leukemia. N Engl J Med 1987; 317:901.
66. Lauria F, Benfenati D, Raspadori D, Rondelli D, Zinzani P L, Tura S. High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine. Leuk Lymph 1993; 11:399-404.
67. Tallman M, Hakimian D, Zanzig C, Rademaker A, Wollins E, Peterson L. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1995; 86 (Suppl 1):608a.
68. von Rohr A, Bacchi M, Fey M F et al. 2-Chlorodeoxyadenosine (CDA) by subcutaneous bolus injection: a phase II study in hairy cell leukemia (HCL). Blood 1995; 86 (Suppl 1):350a.
69. Hoffman M, Janson D, Aggarwal A, Rai K R. Long term results after treatment of hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine (2-CdA). Blood 1995; 86 (Suppl 1):351a.
70. Raemaekers J, vt Vleer M, Verhoef G et al. Two-hours I.V. infusion of 2-chlorodeoxyadenosine (2-CDA) in hairy cell leukemia (HCL) is effective and may produce less CD4/CD8 ratio impairment. Results from the Hovon-23 study. Blood 1995; 86 (Suppl 1):351a.
71. Bastie N J, d'Agay M F, Flandrin G et al. Hairy cell leukemia (HCL): a phase II prospective study about 28 patients treated with 2 chlorodeoxyadenosine (2-CdA). Br J Haematol 1994:87 (Suppl 1):209.
72. Dann E J, Gillis S, Rachmilewitz E A et al. A. Hairy cell leukemia: results of 2-chlorodeoxyadenosine therapy in Jerusalem. Leuk Lymph 1994; 14 (Suppl 1): 127-131.
73. Filleul B, Delannoy A, Ferrant A et al. A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994; 7:1153-1156.
74. Saven A, Piro L D. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2′deoxycoformycin. Ann Intern Med 1993; 119:278-283.
75. Estey E H, Kurzrock R, Kantarjian H et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79:882-887.
76. Hakimian D, Tallman M S, Kiley C, Peterson L. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1993; 82:1798-1802.
77. Ellison D J, Sharpe R W, Robbins B A et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84:4310-4315.
78. Konwalinka G, Schirmer M, Hilbe W et al. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine. Blood Cells, Molecules, and Diseases 1995; 21:142-151.
79. Wheaton S, Tallman M S, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87:1556-1560.
80. Di Celle P F, Reato G, Raspadori D et al. Molecular evaluation of clonal remission in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Leuk Lymph 1994; 14 (Suppl 1): 139-142.
81. Carbone A, Reato G, Di Celle P F, Lauria F, Foa R. Disease eradication in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Leukemia 1994; 8:2019-2021.
82. Seymour J F, Estey E H, Keating M J, Kurzrock R. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. leukemia 1995; 9:929-932.
83. Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol (in press).
84. Delannoy A, Ferrant A, Martiat P et al. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1994; 36:311-315.
85. Rai K R, Sawitsky A, Janson D, Hoffman M. Salvage therapy with 2-chlorodeoxyadenosine (2-CdA) in advanced B-chronic lymphocytic leukemia (CLL) is effective in patients (PTS) without prior fludarabine (F) exposure. Proc Amer Soc Clin Oncol 1994; 13:314a.
86. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327:1056-1061.
87. Saven A, Lemon R H, Piro L D. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993; 328:812-813.
88. Delannoy A, Hanique G, Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993; 328:812.
89. Juliusson G, Liliemark J. 2-Chlorodeoxydenosine therapy in chronic lymphocytic leukemia. N Engl J Med 1994; 330:1828-1829.
90. Saven A, Piro L D. 2-Chlorodeoxydenosine therapy in chronic lymphocytic leukemia. N Engl J Med 1994; 330:1829.
91. Dann E J, Gillis S, Polliack A, Okon E, Rund D, Rachmiliwitz E A. Tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. N Engl J Med 1993; 329:1547-1548.
92. Keating M J, O'Brien S, Kantarjian H et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as single agent. Blood 1993; 81:2878-2884.
93. De Rossi G, Mauro F R, Caruso R, Monarca B, Mandelli F. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages. Haematologica 1993; 78:167-171.
94. Hiddemann W, Rottmann R, Wörmann B et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study. Ann Hematol 1991; 63:1-4.
95. Grever M R, Kopecky K J, Coltman C A et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30:457-459.
96. Puccio C A, Mittleman A, Lichtman S M et al. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocyte leukemia. J Clin Oncol 1991; 9:1562-1569.
97. Bergmann L, Fenchel K, Jahn B, Mitrou P S, Hoeltzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993; 4:371-373.
98. Juliusson G, Liliemark J. Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance. Leuk Lymph 1994; 13:75-80.
99. Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine, CdA) in 177 patients with chronic lymphocytic leukemia (CLL). Blood 1995; 86 (Suppl 1):350a.
100. Mulligan S P, Eliadis P, Dale B et al. 2-Chlorodeoxyadenosine (2-CDA) in previously untreated chronic lymphocytic leukemia (CLL) - preliminary analysis from the Australian Leukemia Study Group trial. Blood 1995; 86 (Suppl 1):349a.
101. Juliusson G, Christiansen I, Mørk Hansen M et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol (In press).
102. O'Brien S, Kantarjian H, Beran M et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82:1695-1700.
103. Cheson B D, Bennett J M, Rai K R et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol 1988; 29:152-163.
104. Robertson L E, Huh Y O, Butler J J et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992; 80;29-36.
105. Cull G, Richardson D S, Howe D J, Hopkins J A, Johnson S A, Phillips M J. Molecular complete response in a patient with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine. Acta Oncologica 1995; 34:536-537.
106. Gala J L, Delannoy A, Martiat P et al. Detection of residual disease by immunostaining of bone marrow trephines (BMT) after 2-chlorodeoxyadenosine (CdA) in previously untreated chronic lymphocytic leukemia (CLL). Blood 1995; 86. (Suppl 1):833a.
107. Dimopoulos M A, Kantarjian H, Weber D et al. Primary treatment of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12:2694-2698.
108. Delannoy A, Ferrant A, Martiat P, Bosly A, Zenebergh A, Michaux J L. 2-Chlorodeoxyadenosine therapy in Waldenström's macroglobulinemia. Nouv Rev Fr Hematol 1994; 36:317-320.
109. Dimopoulos M A, O'Brien S, Kantarjian H, Estey E, Keating M J, Alexanian A. Treatment of Waldenström's macroglobulinemia with nucleoside analogues. Leuk Lymph 1993; 11 (Suppl 2):105-108.
110. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2-Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. Ann Oncol 1994; 5:288-289.
111. Liliemark J, Juliusson G. Intermittent infusion of cladribine (CdA) in previously treated low-grade non Hodgkin's lymphoma (LG-NHL); response, toxicity and survival. Proc Amer Soc Clin Oncol 1995; 14:391a.
112. Khan A, Schiller G, Levine A et al. 2-chloro-2′-deoxyadenosine (2-CDA), an active agent in the treatment of advanced relapsed or refractory low to intermediate grade non-Hodgkin's lymphoma. Proc Amer Soc Clin Oncol 1994; 13:386a.
113. Hickish T, Serafinowski P, Cunningham D et al. T-chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 1993; 67:139-143.
114. Kay A C, Saven A, Carrera C J et al. 2-chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992; 10:371-377.
115. Hoffman M, Tallman M S, Hakimian D et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:788-792.
116. Bosly A, Sonet A, Ferrant A et al. 2-chlorodeoxyadenosine in refractory non-Hodgkin's lymphoma: a phase II study on 50 patients. Blood 1995; 86 (Suppl 1):56a.
117. Liliemark J, Hagsberg H. Cavallin-Ståhl E, Juliusson G. Cladribine (2-CdA) for early low-grade non-Hodgkin's lymphoma (LG NHL). Blood 1994; 84 (Suppl 1):168a.
118. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L D. 2-Chlorodeoxyadenosine activity in patients with untreated indolent non-Hodgkin's lymphoma. Blood 1995; 86:1710-1716.
119. Fridrik M A, Linkesch W, Jäger G et al. Response and toxicity of cladribine (2-CdA) as first line treatment of low-grade non-Hodgkin's lymphomas (NHL). Preliminary data of an Austrian multicenter trial. Blood 1995; 86 (Suppl 1):56a.
120. Rummel M, Leiner L, Hofknecht M et al. 2-CDA-treatment of untreated low grade non Hodgkin lymphomas-preliminary results of a phase-II-study. Blood 1995; 86 (Suppl 1):56a.
121. Piro L D, Petroni G, Barcos M, Johnson J, Saven A, Peterson B. Bolus infusion of 2-chlorodeoxyadenosine (2-CdA) as first-line therapy of low-grade non-Hodgkin's lymphoma (NHL). Blood 1995; 86 (Suppl 1):274a.
122. Saven A, Carrera C J, Carson D A, Beutler E, Piro L D. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992; 80:587-592.
123. Kuzel T M, Hurria A, Samuelson E et al. Phase II trial of 2-chlorodeoxyadenbosine for the treatment of cutaneous T-cell lymphoma. Blood 1996; 87:906-611.
124. Saba H I, Nawab U S, Spiers A S D et al. Purine analogues fludarabine, pentostatin, and cladribine (2Cda) in heavily treated hematological malignancies. Blood 1993; 82 (Suppl 1):577a.
125. Saven A, Tallman M, Hakimian D et al. Treatment of large granular lymphocyte (LGL) leukemia with 2-chlorodeoxyadenosine (2-CdA). Proc Amer Soc Clin Oncol 1995; 14:341a.
126. Lippuner T, Häusermann M, Cerny T, Gutzwiller J P. 2-chlorodeoxyadenosine (2-CDA) leads to partial remission of angioimmunoblastic T-cell lymphoma. Proc Amer Soc Clin Oncol 1995; 14:404a.
127. Gallagher C J, Lister T A. Follicular non-Hodgkin's lymphoma. Baillière's Clinical Haematology 1987; 1:141-155.
128. Zulian G B, Iten P A, Guetty-Alberto M, Antonioli V, Alberto P, Cerny T. Cladribine (2-chlorodeoxyadenosine) with cyclophosphamide and prednisolone as first-line treatment of low grade B-lymphoproliferative disorders. Proc Amer Soc Clin Oncol 1995; 14:400a.
129. Nagourney R A, Evans S S, Messenger J C, Su Y Z, Weisenthal L M. 2 Chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer 1993; 67:10-14.
130. R gene marking. Blood 1995; 86 (Suppl 1):433a.
131. Santana V M, Hurwitz C A, Blakley R L et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994; 84:1237-1242.
132. Santana V M, Mirro J, Kearns C, Schell M J, Crom W, Blakley R L. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed children with acute myeloid leukemia. J Clin Oncol 1992; 10:364-370.
133. Van Den Neste E, Ferrant A, Delannoy A et al. 2-Chlorodeoxyadenosine with or without daunorubicin for relapsing or refractory acute myeloblastic leukemia. Blood 1993; 82 (Suppl 1):129a.
134. Kornblau S, Andreeff M, Beran M et al. 2-CDA ± ARA-C is ineffective therapy for relapsed or refractory AML in adults. Proc Amer Soc Clin Oncol 1995; 14:336a.
135. Juliusson G, Liliemark J. 2-Chlorodeoxyadenosine (CDA) with and without cytosine arabinoside (ARA-C) and idarubicin for acute myloid and lymphoid leukemia- clinical and pharmacokinetic studies. BrJ Haematol 1994; 87 (Suppl 1):12.
136. Rees J H K, Swirsky D, Hayhoe FGH. Principal results of the Medical Research Council's 8th Acute Myeloid Trial. Lancet 1986; ii:1236-1241.
137. Dimopoulos M A, Kantarjian H M, Estey E H, Alexanian R. 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 1992; 80:1626.
138. Delannoy A, Ferrant A, Martiat P, Bosly A, Michaux J L. 2-Chlorodeoxyadenosine and multiple myeloma. Eur J Haematol 1994; 53:181-182.
139. Saven A, Piro L D, Lemon R H et al. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 1994; 73:2953-2963.
140. Nagourney R A, Minow R, Kattlove H et al. Activity of 2-chlorodeoxyadenosine (CDA) in CML blastic crisis (BC). Proc Amer Soc Clin Oncol 1995; 14:489a.
141. Saven A, Figueroa M L, Piro L D, Rosenblatt J D. 2-Chlorodeoxyadenosine to treat refractory histiocytosis. N Engl J Med 1993; 329:734-735.
142. Wayne A S, Tan C T C, Arcesi R J et al. 2-Chlorodeoxyadenosine (2CDA) for disorders of the mono-histiocytic (MO/HI) lineage. Blood 1994; 84 (Suppl 1):57a.
143. Stine K C, Williams L, Saylors R L, Becton D L. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhan's histiocytosis in pediatric patients. Blood 1995; 86 (Suppl 1):510a.
144. Allegretta G, Hurwitz C, Cohen L, Blattner S, Arcesi R. Clinical response to 2-chloro-deoxyadenosine (2-CDA) in a patient with erythrophagocytic lymphohistiocytosis (EL). Proc Amer Soc Clin Oncol 1994; 13:409a.
145. Saven A, Foon K A, Piro L D. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med 1994; 121:430-432.
146. Tallman M, Saven A, Hakimian D et al. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of myelomonocytic leukemias. ASCO Prodeedings 1995:340.
147. Saven A, Lee T, Schlutz M, Longmire R, Piro L. Major activity of 2-chlorodeoxyadenosine (2-CdA) in de novo B-cell prolymphocytic leukemia (B-PLL). Blood 1995; 86 (Suppl 1):350a.
148. Palomera L, Domingo J M, Agulló J A, Romero M S. Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine. J Clin Oncol 1995; 13:1284-1285.
149. Barton K, Larson R A, O'Brien S, Ratain M J. Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. J Clin Oncol; 1992:1821.
150. Kliche K O. Complete remission in a patient with fludarabine-resistant PLL after combined use of 2-CDA and G-CSF. Blood 1995; 86 (Suppl 1):836a.
151. Pless M, Gratwohl A, Tichelli A, Speck B, Betticher D C. 2-Chlorodeoxyadenosine as treatment of severe acute graft-versus-host disease. Blood 1994; 84:987-989.
152. Figueroa M, McMillan R. 2-Chlorodeoxyadenosine in the treatment of chronic refractory immune thrombocytopenic purpura. Blood 1993; 81:3484-3485.
153. Ueno N T, Zhao S, Robertson L E, Consoli U, Andreeff M. 2-Chlorodeoxyadenosine (2-CdA) therapy for idiopathic hypereosinophilic syndrome (ES). Blood 1995; 86 (Suppl 1):803a.
154. Bordeleau L, Bredeson C, Markman S. 2-Chlorodeoxyadenosine therapy for giant lymph node hyperplasia. Br J Haematol 1995; 91:668-670.
155. Tefferi A, Silverstein M N, Li C Y. 2-Chlorodeoxyadenosine (2-CdA) treatment in myelofibrosis with myeloid metaplasia. Blood 1995; 86 (Suppl 1):48a.
156. Lee T C, Miller W E, Curd J G, Piro L D, Saven A. Prolonged complete remission following 2-chlorodeoxyadenosine in a patient with refractory, essential mixed cryoglobulinemia. Mayo Clin Proc (In press).
157. Hiddemann W, Johnson S, Smith A et al. Fludarabine versus cyclophosphamide, adriamycin, prednisone (CAP) for the treatment of chronic lymphocytic leukemia. Blood 1993; 82 (Suppl 1):199a.
158. Binet J L, Chastang C, Chevret S, Dighiero G, Maloum K. Travade P. Comparison of fludarabine (FDB), CAP and CHOP in advanced previously untreated chronic lymphocytic leukemia (CLL). Preliminary results of a randomized clinical trial. Blood 1993; 82 (Suppl 1):140a.
159. Alessi-Severini S, Gati W P, Belch A R, Paterson ARP. Intracellular pharmacokintetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Leukemia 1995; 9:1674-1679.
160. Begleiter A, Verburg L, Ashique A et al. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-ß-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995; 9:1875-1881.